David Oxley

Mr. Oxley serves as Senior Vice President of Business Development & Licensing for Mesoblast, Ltd.  He brings a depth of experience to his role at Mesoblast of more than twenty years-experience across drug and device licensing, drug and device development and approvals, commercialization, and capital markets experience to the company as it transitions through the multiple inflection points in 2020 and beyond. 

Before Mr. Oxley’s tenure at Mesoblast, he served as Chief Executive Officer of Beijing, China-based Lorem Vascular (LV).  LV is a China-based development-stage regenerative medicine company.  Under his leadership, LV grew operations, establishing country offices in Australia, China, Hong Kong, Malaysia, and Singapore, while overseeing the development of IRB-approvable, patient registry studies in heart failure. 

While at LV, Mr. Oxley also served on the board of directors of TB Biosciences, Inc., an antibody-based medical device company.  From his contribution as an Independent Director, the company dramatically reduced a clinical trial specimen collection forecast used in the evaluation of its product.  Also, the company was able to attract and establish a virtual opinion leader network of leading experts in the field of tuberculosis from around the world. 

Before his tenure with LV and TB Biosciences, Mr. Oxley served in executive-level commercial leadership roles with the regenerative medicines company, Cytori Therapeutics.  While at Cytori, Mr. Oxley held key leadership assignments, beginning as vice president of marketing, and concluding as senior vice president for emerging markets & general manager for China. 

Before his tenure at Cytori, Mr. Oxley served a combined eighteen years in leadership positions in the life sciences arena, including head of worldwide sales and marketing for an Irish diagnostics company and global leader of government relations for an infectious diseases company, health-care capital markets for a leading U.S. investment bank, policy advocacy before the U.S. Food and Drug Administration, issue advocacy before the legislative and executive branches of the U.S. government, and health-care legislative work for a then-Representative Ron Wyden (D-Oregon).  Mr. Oxley holds a bachelor’s degree from Portland State University and a Master’s degree from The Johns Hopkins University.